Enzyme‐catalyzed late‐stage functionalization (LSF), such as methylation of drug molecules and lead structures, enables direct access to more potent active pharmaceutical ingredients (API). S‐adenosyl‐l‐methionine‐dependent methyltransferases (MTs) can play a key role in the development of new APIs, as they catalyze the chemo‐ and regioselective methylation of O‐, N‐, S‐ and C‐atoms, being superior to traditional chemical routes. To identify suitable MTs, we developed a continuous fluorescence‐based, high‐throughput assay for SAM‐dependent methyltransferases, which facilitates screening using E. coli cell lysates. This assay involves two enzymatic steps for the conversion of S‐adenosyl‐l‐homocysteine into H2S to result in a selective fluorescence readout via reduction of an azidocoumarin sulfide probe. Investigation of two O‐MTs and an N‐MT confirmed that this assay is suitable for the determination of methyltransferase activity in E. coli cell lysates.
The methylation of small molecules is of immense value to various chemical industries. Since chemical alkylation requires rather unselective and harsh reaction conditions, sustainable biocatalytic approaches are highly desired. Methyltransferases, particularly N ‐methyltransferases (NMTs), facilitate the selective introduction of methyl (and other alkyl) groups under mild conditions in aqueous solution and are a promising alternative to chemical synthesis. In this work, we expanded the toolbox of NMTs through the bioinformatic‐assisted mining of databases and the high‐throughput characterization of novel NMTs by a fluorescence‐based assay. The latter can assess enzyme activity in cell lysates, independent of the investigated substrate, and was used to guide the engineering of newly identified NMTs. Mutants, exhibiting up to 8‐fold improved selective methylation of (non‐)natural N ‐heterocyclic drug precursors, were identified and promise great potential for synthetic applications.
Die enzymkatalysierte Funktionalisierung (engl.: late‐stage functionalization (LSF)), wie z. B. die Methylierung von Arzneimittelmolekülen und Leitstrukturen, ermöglicht den direkten Zugang zu wirksameren pharmazeutischen Wirkstoffen (API). S‐Adenosyl‐l‐Methionin‐abhängige Methyltransferasen (MTs) können eine Schlüsselrolle bei der Entwicklung neuer Wirkstoffe spielen, da sie die chemo‐ und regioselektive Methylierung von O‐, N‐, S‐ und C‐Atomen katalysieren und damit den herkömmlichen chemischen Wegen überlegen sind. Um geeignete MTs zu identifizieren, haben wir einen kontinuierlichen fluoreszenzbasierten Hochdurchsatzassay für SAM‐abhängige Methyltransferasen entwickelt, der das Screening unter Verwendung von E. coli Zelllysaten erleichtert. Dieser Assay besteht aus zwei enzymatischen Schritten für die Umwandlung von S‐Adenosyl‐l‐Homocystein zu H2S, was zu einer selektiven Fluoreszenzmessung durch Reduktion eines Azidocoumarin‐Sulfidsensors führt. Die Untersuchung von zwei O‐MTs und einer N‐MT bestätigte, dass dieser Assay für die Bestimmung der Methyltransferase‐Aktivität in E. coli Zelllysaten geeignet ist.